These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30379624)

  • 1. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
    Getz KD; Sung L; Ky B; Gerbing RB; Leger KJ; Leahy AB; Sack L; Woods WG; Alonzo T; Gamis A; Aplenc R
    J Clin Oncol; 2019 Jan; 37(1):12-21. PubMed ID: 30379624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
    Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
    Gibson BE; Webb DK; Howman AJ; De Graaf SS; Harrison CJ; Wheatley K;
    Br J Haematol; 2011 Nov; 155(3):366-76. PubMed ID: 21902686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
    Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Getz KD; Sung L; Alonzo TA; Leger KJ; Gerbing RB; Pollard JA; Cooper T; Kolb EA; Gamis AS; Ky B; Aplenc R
    J Clin Oncol; 2020 Jul; 38(21):2398-2406. PubMed ID: 32343641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.
    Elgarten CW; Wood AC; Li Y; Alonzo TA; Brodersen LE; Gerbing RB; Getz KD; Huang YV; Loken M; Meshinchi S; Pollard JA; Sung L; Woods WG; Kolb EA; Gamis AS; Aplenc R
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29281. PubMed ID: 34596937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for children with medulloblastoma.
    Michiels EM; Schouten-Van Meeteren AY; Doz F; Janssens GO; van Dalen EC
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD006678. PubMed ID: 25879092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
    Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
    Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group.
    Orgel E; Sposto R; Malvar J; Seibel NL; Ladas E; Gaynon PS; Freyer DR
    J Clin Oncol; 2014 May; 32(13):1331-7. PubMed ID: 24687836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
    Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
    JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
    Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
    Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
    Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
    Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.